{
    "clinical_study": {
        "@rank": "131125", 
        "arm_group": {
            "arm_group_label": "high dose chemo w/asct + maintenance txt", 
            "arm_group_type": "Experimental", 
            "description": "High dose chemotherapy (Carmustine), VP-16 (etoposide, Vepesid\u00ae), Cytarabine (Ara-C), Melphalan (Alkeran)with autologous stem cell transplant followed by maintenance therapy with Romidepsin (Istodax)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in\n      patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous\n      transplantation."
        }, 
        "brief_title": "A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "T Cell Non-Hodgkin Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, T-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary aim is to determine a preliminary estimate of the progression-free survival of\n      patients with T NHL who receive maintenance romidepsin at 2 years post-transplant for\n      patients transplanted in CR1 or PR1 with standard risk histologies.\n\n      Secondary aims include:\n\n        -  Determine PFS at 2 yrs for patients transplanted in \u2265CR/PR2 or for patients with high\n           risk histologies.\n\n        -  Determine the toxicities associated with romidepsin following autologous\n           transplantation\n\n        -  Determine the probability of OS at 2 years post transplant for all patients undergoing\n           transplant\n\n        -  Characterize the effect of romidepsin on immune recovery post HDT-ASCT\n\n        -  OS and PFS 1 year after Romidespin completion"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age:  Patients over age 16 who are deemed eligible for transplant by their treating\n             physician Disease status: CR or PR required.  Remission status will be assessed at\n             the completion of induction chemotherapy and prior to enrollment on protocol.\n\n        Diagnosis: The following histologies will need to be confirmed at MSKCC or locally for\n        participating sites in order to be considered for HDT-ASCT and post-transplant maintenance\n        romidepsin:\n\n          -  PTCL\n\n          -  AITL\n\n          -  ALCL\n\n          -  EaTCL\n\n          -  Hepatosplenic Gamma Delta T cell lymphoma\n\n          -  Adult T-cell leukemia/lymphoma\n\n          -  Primary cutaneous gamma/delta T-cell lymphoma\n\n          -  Extranodal NK/T-cell lymphoma, nasal type\n\n          -  Primary cutaneous anaplastic large cell lymphoma\n\n          -  Subcutaneous panniculitis-like T-cell lymphoma\n\n          -  Mycosis fungoides/sezary syndrome Stem cell collection:  A minimum of 2 x 106 CD34+\n             cells must have been collected\n\n        Laboratory test results within these ranges:\n\n          -  Total bilirubin <= 1.5 x ULN\n\n          -  AST (SGOT) and ALT (SGPT) <= 3 x ULN\n\n        Exclusion Criteria:\n\n          -  \u2022 Diagnosis: progressive disease at transplant work-up\n\n               -  Prior therapy: prior autologous or allogeneic transplant\n\n               -  Active and uncontrolled infection at time of transplantation including active\n                  infection with Aspergillus or other mold, or HIV infection\n\n               -  Inadequate performance status/organ function defined by DLCO < 50% (adjusted for\n                  hgb), cardiac function as defined below, KPS < 60%.\n\n               -  Pregnant or breast feeding.  For males and females of child-producing potential,\n                  inability to use effective contraceptive methods during the study\n\n               -  Prior therapy with romidepsin\n\n               -  Central nervous system or meningeal involvement\n\n               -  Any known cardiac abnormalities such as:\n\n                    -  Congenital long QT syndrome\n\n                    -  QTc interval \u2265 500 milliseconds\n\n                    -  Myocardial infarction within 6 months of transplantation.  Subjects with a\n                       history of myocardial infarction between 6 and 12 months prior to\n                       transplant who are asymptomatic and have had a negative cardiac risk\n                       assessment (treadmill stress test, nuclear medicine stress test, or stress\n                       echocardiogram) since the event may participate\n\n                    -  Other significant ECG abnormalities including 2nd degree atrio-ventricular\n                       (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate\n                       less than 50 beats/min)\n\n                    -  Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class\n                       II-IV (see Appendix 1)  In any patient in whom there is doubt, the patient\n                       should have a stress imaging study and, if abnormal, angiography to define\n                       whether or not CAD is present\n\n                    -  An ECG recorded at screening showing evidence of cardiac ischemia (ST\n                       depression of \u22652 mm, measured from isoelectric line to the ST segment).  If\n                       in any doubt, the patient should have a stress imaging study and, if\n                       abnormal, angiography to define whether or not CAD is present\n\n                    -  Congestive heart failure (CHF) that meets New York Heart Association (NYHA)\n                       Class II to IV definitions (see Appendix 2) and/or ejection fraction <40%\n                       by MUGA scan or <50% by echocardiogram and/or MRI\n\n                    -  A known history of sustained ventricular tachycardia (VT), ventricular\n                       fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently\n                       addressed with an automatic implantable cardioverter defibrillator (AICD)\n\n                    -  Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior\n                       treatment or other causes\n\n                    -  Uncontrolled hypertension, defined as blood pressure (BP) of \u2265160/95;\n                       patients who have a history of hypertension controlled by medication must\n                       be on a stable dose (for at least one month) and meet all other inclusion\n                       criteria\n\n                    -  Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding\n                       stable doses of beta-blockers)\n\n                    -  Patients taking drugs leading to significant QT prolongation within the\n                       specified wash out period (See Appendix 3: Medications That May Cause QTc\n                       Prolongation).\n\n                    -  Concomitant use of CYP3A4 inhibitors"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01908777", 
            "org_study_id": "13-020"
        }, 
        "intervention": {
            "arm_group_label": "high dose chemo w/asct + maintenance txt", 
            "intervention_name": "High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin", 
            "intervention_type": "Other", 
            "other_name": [
                "Carmustine", 
                "VP-16 (etoposide, Vepesid\u00ae)", 
                "Cytarabine (Ara-C)", 
                "Melphalan (Alkeran)", 
                "Romidepsin (Istodax)"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Carmustine", 
                "Melphalan", 
                "Romidepsin", 
                "Cytarabine", 
                "Etoposide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 10, 2014", 
        "link": {
            "description": "Memorial Sloan Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Jenna Goldberg, MD", 
                    "phone": "212-639-4828"
                }, 
                "facility": {
                    "address": {
                        "city": "Basking Ridge", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "Memoral Sloan Kettering Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jenna Goldberg, MD", 
                    "phone": "212-639-4828"
                }, 
                "facility": {
                    "address": {
                        "city": "Commack", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11725"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center @ Suffolk"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jia Ruan, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Weill Cornell Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jia Ruan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jenna Goldberg, MD", 
                    "phone": "212-639-4828"
                }, 
                "contact_backup": {
                    "last_name": "Steven Horwitz, MD", 
                    "phone": "212-639-3045"
                }, 
                "facility": {
                    "address": {
                        "city": "NY", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Jenna Goldberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jenna Goldberg, MD", 
                    "phone": "212-639-4828"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockville Centre", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Memorial Sloan-Kettering at Mercy Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jenna Goldberg, MD", 
                    "phone": "212-639-4828"
                }, 
                "facility": {
                    "address": {
                        "city": "Sleepy Hollow", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10591"
                    }, 
                    "name": "Memoral Sloan Kettering Cancer Center at Phelps"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andrei Shustov, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "University of Washington School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Andrei Shustov, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma", 
        "overall_contact": {
            "last_name": "Jenna Goldberg, MD", 
            "phone": "212-639-4828"
        }, 
        "overall_contact_backup": {
            "last_name": "Steven Horowitz, MD", 
            "phone": "212-639-3045"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Jenna Goldberg, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The progression-free survival of patients with T NHL who receive maintenance romidepsin at 2 years post-transplant for patients transplanted in CR1 or PR1 with standard risk histologies.", 
            "measure": "The progression-free survival of patients", 
            "safety_issue": "No", 
            "time_frame": "2 Years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01908777"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Determine PFS at 2 yrs for patients transplanted in \u2265CR/PR2 or for patients with high risk histologies.", 
                "measure": "Progression Free Survival for patients with high risk histologies", 
                "safety_issue": "No", 
                "time_frame": "2 Years"
            }, 
            {
                "description": "Determine the toxicities associated with romidepsin following autologous transplantation. Toxicities will be graded on a scale of 0 to 5 as described by the NCI- Common Terminology for Adverse Events (CTCAE), version 4.0", 
                "measure": "Toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Determine the probability of OS at 2 years post transplant for all patients undergoing transplant", 
                "measure": "Probability of OS at 2 years post transplant", 
                "safety_issue": "No", 
                "time_frame": "2 year post transplant"
            }, 
            {
                "description": "OS 1 year after Romidespin completion", 
                "measure": "OS 1 year after Romidespin completion", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "PFS 1 year after Romidespin completion", 
                "measure": "PFS 1 year after Romidespin completion", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Washington", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Weill Medical College of Cornell University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}